These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

236 related items for PubMed ID: 7858542

  • 1. Graft-versus-host disease following interferon therapy for relapsed chronic myeloid leukaemia post-allogeneic bone marrow transplantation.
    Browett PJ, Nelson J, Tiwari S, Van de Water NS, May S, Palmer SJ.
    Bone Marrow Transplant; 1994 Oct; 14(4):641-4. PubMed ID: 7858542
    [Abstract] [Full Text] [Related]

  • 2. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF, Marijt EW, Barge RM, van Soest RA, Baas IO, Starrenburg CW, van Zelderen-Bhola SL, Fibbe WE, Smit WM, Willemze R, Falkenburg JH.
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [Abstract] [Full Text] [Related]

  • 3. Atypical chronic graft-versus-host disease following interferon therapy for chronic myeloid leukaemia relapsing after allogeneic BMT.
    Serrano J, Prieto E, Mazarbeitia F, Román A, Llamas P, Tomás JF.
    Bone Marrow Transplant; 2001 Jan; 27(1):85-7. PubMed ID: 11244442
    [Abstract] [Full Text] [Related]

  • 4. Achievement of complete cytogenetic remission after two very low-dose donor leucocyte infusions in a patient with extensive cGVHD relapsing in accelerated phase post allogeneic BMT for CML.
    Rahman SL, Mahendra P, Nacheva E, Sinclair P, Arno J, Marcus RE.
    Bone Marrow Transplant; 1998 May; 21(9):955-6. PubMed ID: 9613792
    [Abstract] [Full Text] [Related]

  • 5. Role of splenic irradiation in patients with chronic myeloid leukemia undergoing allogeneic bone marrow transplantation.
    Jabro G, Koc Y, Boyle T, Schenkein DP, Ravalese J, Wazer D, Miller KB.
    Biol Blood Marrow Transplant; 1999 May; 5(3):173-9. PubMed ID: 10392963
    [Abstract] [Full Text] [Related]

  • 6. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK, Parikh PM, Tawde S, Amare-Kadam PS, Rajadhyaksha S, Chhaya S.
    Natl Med J India; 2004 May; 17(2):71-3. PubMed ID: 15141598
    [Abstract] [Full Text] [Related]

  • 7. Molecular remission induced by fractionated dose-escalating donor leukocyte infusion without graft-versus-host disease in a patient with chronic myelogenous leukemia relapsed after allogeneic bone marrow transplantation.
    Inai K, Wano Y, Yamamoto S, Ikebata Y, Iwasaki H, Tsutani H, Naiki H, Ueda T.
    Anticancer Res; 1999 May; 19(6C):5631-4. PubMed ID: 10697631
    [Abstract] [Full Text] [Related]

  • 8. Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes.
    Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R.
    Exp Hematol; 1995 Dec; 23(14):1553-62. PubMed ID: 8542946
    [Abstract] [Full Text] [Related]

  • 9. Persistent donor chimaerism is consistent with disease-free survival following BMT for chronic myeloid leukaemia.
    Gardiner N, Lawler M, O'Riordan J, DeArce M, Humphries P, McCann SR.
    Bone Marrow Transplant; 1997 Aug; 20(3):235-41. PubMed ID: 9257892
    [Abstract] [Full Text] [Related]

  • 10. Donor lymphocyte infusions (DLI) in patients with chronic myeloid leukemia following allogeneic bone marrow transplantation.
    Bacigalupo A, Soracco M, Vassallo F, Abate M, Van Lint MT, Gualandi F, Lamparelli T, Occhini D, Mordini N, Bregante S, Figari O, Benvenuto F, Sessarego M, Fugazza G, Carlier P, Valbonesi M.
    Bone Marrow Transplant; 1997 May; 19(9):927-32. PubMed ID: 9156268
    [Abstract] [Full Text] [Related]

  • 11. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K, Minami S, Ueda T, Nishimura M, Tsubaki K, Takemoto Y, Takeshita A, Sao H, Kageyama S, Ueda R, Ohno R.
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [Abstract] [Full Text] [Related]

  • 12. Prior treatment with alpha-interferon does not adversely affect the outcome of allogeneic BMT in chronic phase chronic myeloid leukemia.
    Zuffa E, Bandini G, Bonini A, Santucci MA, Martinelli G, Rosti G, Testoni N, Zaccaria A, Tura S.
    Haematologica; 1998 Mar; 83(3):231-6. PubMed ID: 9573677
    [Abstract] [Full Text] [Related]

  • 13. Interferon-alpha and interleukin-2 as treatment for leukemia relapse after allogeneic bone marrow transplantation.
    Giralt S, O'Brien S, Talpaz M, Van Besien K, Chan KW, Rondón G, Andersson B, Mehra R, Khouri I, Estey E.
    Cytokines Mol Ther; 1995 Jun; 1(2):115-22. PubMed ID: 9384668
    [Abstract] [Full Text] [Related]

  • 14. Unrelated allogeneic bone marrow transplantation using high-dose busulfan and cyclophosphamide (BU-CY) for the preparative regimen.
    Sahebi F, Copelan E, Crilley P, Bolwell B, Avalos B, Klein J, Territo M, Gajewski J.
    Bone Marrow Transplant; 1996 May; 17(5):685-9. PubMed ID: 8733682
    [Abstract] [Full Text] [Related]

  • 15. Interferon alpha for chronic myeloid leukemia relapsing after allogeneic bone marrow transplantation.
    Steegmann JL, Casado LF, Tomás JF, Sanz-Rodríguez C, Granados E, de la Cámara R, Alegre A, Vázquez L, Ferro MT, Figuera A, Arranz R, Fernández-Rañada JM.
    Bone Marrow Transplant; 1999 Mar; 23(5):483-8. PubMed ID: 10100563
    [Abstract] [Full Text] [Related]

  • 16. Phimosis as a manifestation of chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Kami M, Kanda Y, Sasaki M, Takeda N, Tanaka Y, Saito T, Ogawa S, Honda H, Chiba S, Mitani K, Hirai H, Yazaki Y.
    Bone Marrow Transplant; 1998 Apr; 21(7):721-3. PubMed ID: 9578313
    [Abstract] [Full Text] [Related]

  • 17. Adoptive immunotherapy for relapse of chronic myeloid leukemia after allogeneic bone marrow transplant: equal efficacy of lymphocytes from sibling and matched unrelated donors.
    van Rhee F, Savage D, Blackwell J, Orchard K, Dazzi F, Lin F, Chase A, Bungey J, Cross NC, Apperley J, Szydlo R, Goldman JM.
    Bone Marrow Transplant; 1998 May; 21(10):1055-61. PubMed ID: 9632281
    [Abstract] [Full Text] [Related]

  • 18. Donor leukocyte infusion for Japanese patients with relapsed leukemia after allogeneic bone marrow transplantation: lower incidence of acute graft-versus-host disease and improved outcome.
    Shiobara S, Nakao S, Ueda M, Yamazaki H, Takahashi S, Asano S, Yabe H, Kato S, Imoto S, Maruta A, Yoshida T, Gondo H, Morishima Y, Kodera Y.
    Bone Marrow Transplant; 2000 Oct; 26(7):769-74. PubMed ID: 11042659
    [Abstract] [Full Text] [Related]

  • 19. [Leukocyte transfusion as therapy of recurrent CML after allogenic bone marrow transplantation].
    Wiesneth M, Hertenstein B, Bunjes D, Novotny J, Stefanic M, Heinze B, Schreiner T, Kubanek B, Heimpel H, Arnold R.
    Beitr Infusionsther Transfusionsmed; 1994 Oct; 32():276-80. PubMed ID: 9480108
    [Abstract] [Full Text] [Related]

  • 20. High-titre interferon-alpha antibodies in a patient with chronic graft-versus-host disease after allogeneic bone marrow transplantation.
    Prümmer O, Bunjes D, Wiesneth M, Arnold R, Porzsolt F, Heimpel H.
    Bone Marrow Transplant; 1994 Sep; 14(3):483-6. PubMed ID: 7994279
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.